Evidence map›Paper›PMID 42432673›Full record

ReviewJournal of translational medicine2026

The NLRP3 inflammasome as a dynamic context-dependent regulator: mechanisms, disease progression, and therapeutic implications.

Shuo Liu, Xun Liu, Jing Hu, He Chen, Siwen Yang, Juan Feng, Yi Sui

Abstract readReview
In one paragraph

Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuo LiuThe Fourth People's Hospital of Shenyang, Shenyang, Liaoning Province, China. wertyy2004@163.com.ORCID http://orcid.org/0000-0001-6507-229X
Xun LiuThe Fourth People's Hospital of Shenyang, Shenyang, Liaoning Province, China.
Jing HuThe Fourth People's Hospital of Shenyang, Shenyang, Liaoning Province, China.
He ChenThe Fourth People's Hospital of Shenyang, Shenyang, Liaoning Province, China.
Siwen YangDepartment of Science, Yokohama City University, Yokohama, Japan.
Juan FengDepartment of Neurology, Shengjing Hospital of China Medical University, China Medical University, Shenyang, China.
Yi SuiThe Fourth People's Hospital of Shenyang, Shenyang, Liaoning Province, China.

Funding

the Applied and Basic Research Program of Liaoning Province 2022JH2/101500058the National Natural Science Foundation of China 82271275
6 · The paper itself

Abstract

The NLRP3 inflammasome is a central regulator of innate immunity and inflammation, but its functions extend beyond a simple pro-inflammatory role. Increasing evidence indicates that the biological consequences of NLRP3 activation are highly context-dependent, with protective or pathogenic effects determined by cellular composition, tissue microenvironment, and disease stage. In this review, we examine NLRP3 biology across three interconnected dimensions: cellular context, including immune and non-immune compartments; microenvironmental context, including infectious versus sterile inflammation and tissue repair versus tissue damage; and disease context, including stage- and time-dependent functional shifts. We further discuss three major determinants of NLRP3 output: cytokine bias between IL-1β and IL-18, cell-fate decisions between pyroptosis and survival, and epigenetic programming of inflammasome-responsive states. Using representative disease settings such as cancer, inflammatory bowel disease, and autoimmune disorders, we illustrate how similar NLRP3 activation can lead to divergent biological outcomes. We also discuss the therapeutic implications of this plasticity, arguing that effective intervention will require context-selective rather than universal inhibition. A more precise understanding of NLRP3 context dependence may support rational trial design, biomarker development, future patient-stratification frameworks, and more biologically informed therapeutic strategies in NLRP3-related diseases.

Indexed as

Disease ProgressionInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsHumansInflammationInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinCancerContext-dependent functionIL-18IL-1βInflammatory bowel diseaseNLRP3 inflammasomePrecision medicinePyroptosis

Identifiers

PMID42432673
PMCPMC13640368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.